Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XLRN
CUSIPN/A
Phone617-649-9200
Debt
Debt-to-Equity RatioN/A
Current Ratio23.21
Quick Ratio23.21
Price-To-Earnings
Trailing P/E Ratio-17.28
Forward P/E Ratio-19.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.48 million
Price / Sales157.24
Cash FlowN/A
Price / CashN/A
Book Value$8.07 per share
Price / Book5.74
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-108,450,000.00
Net Margins-839.98%
Return on Equity-34.52%
Return on Assets-32.40%
Miscellaneous
Employees139
Outstanding Shares45,780,000
Market Cap$2,118.94
Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions
What is Acceleron Pharma's stock symbol?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
How were Acceleron Pharma's earnings last quarter?
Acceleron Pharma Inc (NASDAQ:XLRN) issued its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.06. The biopharmaceutical company had revenue of $3.23 million for the quarter, compared to analyst estimates of $3.77 million. Acceleron Pharma had a negative net margin of 839.98% and a negative return on equity of 34.52%. The firm's revenue for the quarter was down 12.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.66) earnings per share. View Acceleron Pharma's Earnings History.
When is Acceleron Pharma's next earnings date?
What price target have analysts set for XLRN?
13 equities research analysts have issued twelve-month price objectives for Acceleron Pharma's shares. Their predictions range from $32.00 to $74.00. On average, they expect Acceleron Pharma's share price to reach $51.60 in the next year. This suggests a possible upside of 11.4% from the stock's current price. View Analyst Ratings for Acceleron Pharma.
What is the consensus analysts' recommendation for Acceleron Pharma?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Acceleron Pharma stock?
Here are some recent quotes from research analysts about Acceleron Pharma stock:
- 1. Cann analysts commented, "While we have not modeled ACE-083 into our outlook for Track designation received in May 2018 has the potential to move the timeline for Status announced today has the potential to positively impact pricing and exclusivity of ACE-083 in the FSHD setting. Based on this development and recently released positive results for ACE-083, we believe this program will continue to advance and will likely become a marketed drug. ACE-083 could provide upside to our outlook." (7/12/2018)
- 2. HC Wainwright analysts commented, "Preliminary ACE-083 Phase 2 Data Demonstrates Serious Gains in FSHD; Part 2 Current Underway Data demonstrates dose-dependent increases in total muscle volume. This morning, Acceleron Pharma announced preliminary results from the ongoing Phase 2 trial of ACE-083 in facioscapulohumeral muscular dystrophy (FSHD) from the 150 and 200mg arms at the American Academy of Neurology (AAN) 70th Annual Meeting, which is being held in Los Angeles. ACE-083 demonstrated dose-dependent increases in total muscle volume in both the Tibalis Anterior (TA) and Biceps Brachii (BB) muscle cohorts, with a 15-20% increase observed at the higher dose level. In addition, a decrease in fat fraction was observed in both cohorts, however, it was more notable in the TA cohort. With regard to safety, ACE-083 was safe and generally well-tolerated in subjects for up to three months, which included five doses." (4/26/2018)
- 3. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)
Who are some of Acceleron Pharma's key competitors?
Some companies that are related to Acceleron Pharma include Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Halozyme Therapeutics (HALO), Momenta Pharmaceuticals (MNTA), Repligen (RGEN), Atara Biotherapeutics (ATRA) and Editas Medicine (EDIT).
Who are Acceleron Pharma's key executives?
Acceleron Pharma's management team includes the folowing people:
- Mr. Habib J. Dable, CEO, Pres & Director (Age 49)
- Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 75)
- Mr. Kevin F. McLaughlin, CFO, Sr. VP & Treasurer (Age 62)
- Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 58)
- Dr. Matthew L. Sherman, Chief Medical Officer & Exec. VP (Age 62)
Has Acceleron Pharma been receiving favorable news coverage?
Media headlines about XLRN stock have trended somewhat positive recently, according to Accern. The research group scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acceleron Pharma earned a coverage optimism score of 0.11 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 44.97 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Acceleron Pharma's major shareholders?
Acceleron Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Neville Rodie & Shaw Inc. (0.09%), Verde Servicos Internacionais S.A. (0.02%), Campbell & CO Investment Adviser LLC (0.02%) and Amalgamated Bank (0.01%). Company insiders that own Acceleron Pharma stock include Christopher Rovaldi, Corp /De/ Celgene, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.
Which major investors are selling Acceleron Pharma stock?
XLRN stock was sold by a variety of institutional investors in the last quarter, including Verde Servicos Internacionais S.A.. Company insiders that have sold Acceleron Pharma company stock in the last year include Christopher Rovaldi, Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar and Richard F Pops. View Insider Buying and Selling for Acceleron Pharma.
Which major investors are buying Acceleron Pharma stock?
XLRN stock was acquired by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc., Campbell & CO Investment Adviser LLC and Amalgamated Bank. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.
How do I buy shares of Acceleron Pharma?
Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acceleron Pharma's stock price today?
One share of XLRN stock can currently be purchased for approximately $46.30.
How big of a company is Acceleron Pharma?
Acceleron Pharma has a market capitalization of $2.12 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe.
How can I contact Acceleron Pharma?
Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]
MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
